Antiplatelet therapy is the mainstay for the treatment of acute and chronic arterial disease
involving the coronary and peripheral beds. However, questions remain about optimal …

Direct oral anticoagulants (DOACs) account for most oral anticoagulant use. DOAC-
associated bleeding events are commonly encountered in clinical practice and are …

Rationale: A reduced rate of myocardial infarction has been reported in patients with atrial
fibrillation treated with FXa (factor Xa) inhibitors including rivaroxaban compared with …

Platelets play a significant role in atherothrombosis. Proprotein convertase subtilisin/kexin
type 9 (PCSK9) is critically involved in the regulation of LDL metabolism and interacts with …

Platelet ACKR3/CXCR7 surface expression is enhanced and influences prognosis in
coronary artery disease (CAD) patients, who exhibit a distinct atherothrombotic platelet …

Various antithrombotic agents are clinically used to inhibit the cascade of arterial or venous
thrombosis in cardiovascular diseases. Dual antiplatelet therapy with aspirin and P2Y 12 …

Atherosclerosis is a systemic disease with different faces. Despite identical or similar
pathogenetic mechanisms, atherosclerotic lesions and their clinical manifestations vary in …

Introduction The persistence of elevated rates of ischemic recurrences despite the use of
antiplatelet therapy among patients with atherosclerotic disease together with the …

Despite advances in secondary prevention strategies in patients with cardiovascular
disease, the residual risk of recurrent atherothrombotic events remains high. Dual …

Background Vorapaxar as an adjunct to dual antiplatelet therapy (DAPT) reduces thrombotic
events in patients with prior myocardial infarction at the expense of increased bleeding …